CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,049 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01097655
NCT01097655N/ACompleted

Use of KALETRA® Tablets in Adult HIV-infected Patients: Data From the Multicenter Star/Stella Cohort

AbbVie (prior sponsor, Abbott)·observational·Posted Apr 2, 2010·Updated May 23, 2017

In Brief

An observational study for Human Immunodeficiency Virus. Completed, enrolled 3,049 participants.

Detailed Summary

The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients. In some patients, the study is to show the impact on tolerability of changing therapy to Kaletra tablets from other regimens.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2, 2010
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 16.3 years ago